Prostate Cancer

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

Prostate cancer is slow-growing and readily curable in many cases, but the propensity for some tumors to develop into an aggressive, metastatic form that becomes resistant to androgen-targeting therapies continues to present a significant obstacle.

After updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial were presented earlier this year, members of the oncology community strongly suggested that the United States Preventative Services Task Force revise its views on prostate-specific antigen screening for patients with prostate cancer.

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.

Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses resistance to antiandrogen therapy in prostate cancer.

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

Pfizer has announced plans to acquire the biopharmaceutical company Medivation, which is the developer of the androgen receptor inhibitor enzalutamide (Xtandi).

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

Adding custirsen to cabazitaxel (Jevtana) and prednisone in the second-line setting failed to improve overall survival in men with metastatic castration-resistant prostate cancer in the phase III AFFINITY trial.

Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

​Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Gregory Zagaja, MD, discusses the benefits of radical prostatectomy and other ongoing developments with surgery in prostate cancer.

Russell Szmulewitz, MD, discusses optimal treatment strategies for patients with metastatic castration-resistant prostate cancer and highlights emerging therapies in the therapeutic landscape.